Related Experiment Video

Updated: Apr 26, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K

[Treatment progress for EGFR wild-type advanced non-small cell lung cancer]

Feng Ma1, Xiaoyu Shi1, Wei Meng1

  • 1Department of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|July 19, 2014
PubMed

Insights

For non-small cell lung cancer (NSCLC) patients without EGFR mutations, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) show limited efficacy. This review explores optimal treatment strategies for EGFR wild-type NSCLC.

Area of Science:

  • Oncology
  • Medical Research
  • Clinical Trials

Background:

  • Lung cancer is the leading global cause of cancer mortality.
  • Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have improved non-small cell lung cancer (NSCLC) treatment.
  • Limited efficacy of EGFR-TKIs in EGFR wild-type NSCLC necessitates alternative therapeutic approaches.

Purpose of the Study:

  • To review the current research on treatment choices for NSCLC patients who are negative for EGFR mutations.
  • To identify and discuss optimal therapeutic strategies for EGFR wild-type NSCLC.

Main Methods:

  • Literature review of existing research.
  • Analysis of clinical trial data.
  • Synthesis of current treatment guidelines.

Main Results:

  • EGFR-TKI efficacy is restricted in patients with wild-type EGFR.
  • The incidence of EGFR mutations is limited, highlighting the need for alternative treatments.
  • Research is ongoing to determine the best treatment options for EGFR wild-type NSCLC.

Conclusions:

  • Optimal treatment selection for EGFR wild-type NSCLC remains a significant clinical challenge.
  • Further research is crucial to establish effective therapies for this patient subgroup.
  • Exploring novel treatment modalities is essential for improving outcomes in EGFR wild-type NSCLC.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K